These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 28449418)

  • 1. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism.
    Haase VH
    Hemodial Int; 2017 Jun; 21 Suppl 1(Suppl 1):S110-S124. PubMed ID: 28449418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.
    Sanghani NS; Haase VH
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):253-266. PubMed ID: 31477256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
    Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
    J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roxadustat: First Global Approval.
    Dhillon S
    Drugs; 2019 Apr; 79(5):563-572. PubMed ID: 30805897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
    Gupta N; Wish JB
    Am J Kidney Dis; 2017 Jun; 69(6):815-826. PubMed ID: 28242135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors
    Yang J; Xing J; Zhu X; Xie X; Wang L; Zhang X
    Front Endocrinol (Lausanne); 2023; 14():1131516. PubMed ID: 37008953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
    Provenzano R; Tumlin J; Zabaneh R; Chou J; Hemmerich S; Neff TB; Yu KP
    J Clin Pharmacol; 2020 Nov; 60(11):1432-1440. PubMed ID: 32603526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients.
    Locatelli F; Fishbane S; Block GA; Macdougall IC
    Am J Nephrol; 2017; 45(3):187-199. PubMed ID: 28118622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review.
    Kile M; Sudchada P
    Int Urol Nephrol; 2021 Feb; 53(2):283-290. PubMed ID: 32770437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel scenario in the therapeutic management of anemia of chronic kidney disease: placement and use of roxadustat.
    Locatelli F; Ravera M; Esposito C; Grandaliano G; Gesualdo L; Minutolo R
    J Nephrol; 2024 May; 37(4):1107-1119. PubMed ID: 38189866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
    Kurata Y; Tanaka T; Nangaku M
    Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):414-422. PubMed ID: 32452915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
    Kular D; Macdougall IC
    Pediatr Nephrol; 2019 Mar; 34(3):365-378. PubMed ID: 29569190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis.
    Li J; Xie QH; You L; Xu NX; Hao CM
    Pharmacol Res; 2021 Jan; 163():105256. PubMed ID: 33086081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
    Maruno S; Tanaka T; Nangaku M
    Rinsho Ketsueki; 2021; 62(5):371-377. PubMed ID: 34108317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roxadustat in the treatment of anaemia in chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jan; 27(1):125-133. PubMed ID: 29254377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease and Renal Anemia.
    Packer M
    Am J Nephrol; 2024; 55(2):255-259. PubMed ID: 37231827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease.
    Sugahara M; Tanaka T; Nangaku M
    Kidney Int; 2017 Aug; 92(2):306-312. PubMed ID: 28651951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.
    Akizawa T; Tsubakihara Y; Nangaku M; Endo Y; Nakajima H; Kohno T; Imai Y; Kawase N; Hara K; Lepore J; Cobitz A
    Am J Nephrol; 2017; 45(2):127-135. PubMed ID: 27978511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.